English
Choose your country/region and language
Your experience may change as only information for the country or region you select will be presented.
Confidence in Your Results
Our high-quality assays enable researchers to detect and quantify blood-based biomarkers for neurodegenerative diseases with the exceptional sensitivity and specificity you’ve come to expect from Beckman Coulter.
And our partnerships with world-class research centers facilitate a deeper understanding of biomarkers involved in conditions such as Alzheimer's disease.
ACCESS Blood-based Neurodegenerative Disease Assays
| Assays for Research Use Only | IFU | Information Bulletin |
| BD-pTau 217 | Link | Link |
| p-Tau217 | Link | Link |
| GFAP | Link | Link |
| NfL | Link | Link |
| APOE ε4 | Link | Link |
| ß-AmyIoid 1-42 | Link | Link |
| BD-Tau | Link | Link |
| Research Use Only Assays in Development | ||
| p‑Tau205 | ||
For Research Use Only. Not for use in diagnostic procedures.
Advance Alzheimer's disease research with high-specificity detection of brain-derived p-Tau217
The high-specificity, automated Access BD-pTau217 RUO assay enables improved biological differentiation and supports disease staging in Alzheimer's disease research:
- Selectively detects brain-derived pTau217, reducing contribution from peripheral tau signal in plasma-based studies
- Supports research into disease staging, progression, and key inflection points
- Enables improved characterization and stratification of research populations, including complex or real-world cohorts
Explore analytical performance and assay design
Poster: A New High-Throughput, Fully Automated Immunoassay for Plasma Brain-Derived pTau217
For Research Use Only. Not for use in diagnostic procedures.
Fully Automated APOE ε4 Testing
Our APOE ε4 RUO blood-based immunoassay offers >99% concordance with PCR genotyping—in only 20 minutes.
“We are investing in our immunoassay technology to develop new, blood-based, high throughput, high sensitivity assays to detect and measure neurological biomarkers at a scale to address the growing global challenge."
Group Executive, Diagnostics, Danaher
Building on our legacy of innovation, we are advancing the future of diagnostics around the globe to deliver accurate,
affordable testing solutions at scale.
High-throughput and highly sensitive. Our patented Lumi-Phos PRO substrate comes to full glow in under a minute.
Westgard analysis showed that the DxI 9000 analyzer had more assays achieving 6σ than any of our competitors
PrecisionVision technology directly monitors critical assay processing steps to identify errors and direct course correction in real time.
Educational Resources
Your Research fueled by blood-based biomarkers
Learn more about Beckman Coulter's panel of highly sensitive RUO neurodegenerative disease markers here
Request More Information
Thank you for your request.
A Beckman Coulter representative will contact you shortly.
1. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e125.https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(21)00249-8/fulltext
2. World Health Organization. Parkinson disease. August 9, 2023. Accessed February 7, 2025. https://www.who.int/news-room/fact-sheets/detail/parkinson-disease
3. Guan B, Anderson DB, Chen L, Feng S, Zhou H. Global, regional and national burden of traumatic brain injury and spinal cord injury, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. BMJ Open. 2023;13(10):e075049. https://bmjopen.bmj.com/content/13/10/e075049
4. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816-1821. https://pubmed.ncbi.nlm.nih.gov/33174475/"doi:10.1177/1352458520970841
MAPSS-3272-GLB-EN-v2
